Home button
About US button
Your Visit button
About Cancer button
Clinical Trials button
Publications and Research button
Cancer Therapies button
Cancer Effects button
How you can Help button
Links button

Publications & Research

Publications: Dr. Michael Lewis

Lewis MR, Raubitschek A, Shively JE. A facile, water-soluble method for modification of proteins with DOTA: Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem 5: 565-576, 1994. [Abstract]

Lewis MR, Shively JE. Maleimidocysteineamido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjugate Chem 9: 72-86, 1998. [Abstract]

Williams LE, Lewis MR, Bebb GG, Clarke KG, Odom-Maryon TL, Shively JE, Raubitschek AA. Biodistribution of 111In- and 90Y-Labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anti-carcinoembryonic antigen antibody in xenograft-bearing nude mice: Comparison of stable and chemically labile linker systems. Bioconjugate Chem 9: 87-93, 1998. [Abstract]

Publications: Dr. Henry
Publications: Dr. Lattimer
Publications: Dr. Lewis
Publications: Dr. Selting

Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 42: 1341-1347, 1999. [Abstract]

Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive tumor-bearing rat model. Clin Cancer Res 5: 3608-3616, 1999. [Abstract]

Lewis MR, Kao JY, Anderson A-LJ, Shively JE, Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjugate Chem 12: 320-324, 2001. [Abstract]

Lewis MR, Boswell CA, Laforest R, Buettner TL, Ye D, Connett JM, Anderson CJ. Conjugation of monoclonal antibodies with TETA using activated esters: Biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3. Cancer Biother Radiopharm 16: 483-494, 2001. [Abstract]

Lewis MR, Reichert DE, Laforest R, Margenau W.H, Shefer RE, Klinkowstein RE, Hughey BJ, Welch MJ. Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals. Nucl Med Biol 29: 701-706, 2002. [Abstract]

Lewis MR, Jia F, Gallazzi F, Wang Y, Zhang J, Shenoy N, Lever, S.Z., and Hannink, M. Radiometal-Labeled Peptide-PNA Conjugates for Targeting bcl-2 Expression: Preparation, Characterization, and in vitro mRNA Binding. Bioconjugate Chem 13:1176-1180, 2002. [Abstract]

Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med 44(8):1284-92, 2003 [Abstract]

Lewis MR, Jia F. Antisense imaging: and miles to go before we sleep? J Cell Biochem 90: 464-472, 2003 [Abstract]

Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Yang Z-F, Waters DJ, Snyder PW, Low PS, Welch MJ, Green MA. Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl Med Biol 30: 725-731, 2003 [Abstract]

Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 63: 6864-6869, 2003 [Abstract]

Gallazzi F, Wang Y, Jia F, Shenoy N, Landon LA, Hannink M, Lever SZ, Lewis MR. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene. Bioconjugate Chem 14: 1083-1095, 2003 [Abstract]

Lewis MR, Zhang J, Jia F, Owen NK, Cutler CS, Embree MF, Schultz J, Theodore LJ, Ketring AR, Jurisson SS, Axworthy DB. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol 31(2):213-23, 2004. [Abstract]

Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Vet Comp Oncol 2004; 2:82-90. [Abstract]

Lewis MR. Radiolabeled RGD peptides move beyond cancer: PET imaging of delayed-type hypersensitivity reaction.
J Nucl Med. 2005; 46(1):2-4. [Abstract]